ROBIN:整合术中甲基化分类与次日综合分析的纳米孔统一检测用于超快速肿瘤诊断
ROBIN 是基于 PromethION 纳米孔测序的工具,可在单次检测中提供实时术中甲基化分类和次日综合分子分析。在 50 例前瞻性术中病例中,诊断周转时间不足 2 小时,分类器与最终整合诊断的一致率为 90%。纳米孔测序可大幅缩短标准诊断周转时间,并可靠提供术中可操作的肿瘤分类。
要点
- ROBIN 整合术中甲基化分类与次日综合分子分析于单次纳米孔测序检测。
- 50 例前瞻性术中病例诊断周转时间不足 2 小时,分类器与最终整合诊断一致率 90%。
- ROBIN 可实时检测单核苷酸变异、拷贝数变异和结构变异,24 小时内形成完整整合诊断。
核心结论
- 纳米孔测序可大幅改善标准诊断检测的周转时间,并能可靠提供临床可操作的术中肿瘤分类。
研究设计与样本
- 基于 PromethION 纳米孔测序技术的 ROBIN 工具,采用 3 种甲基化分类器,在 50 例前瞻性术中病例中评估分类器性能。
主要发现
- 在 50 例前瞻性术中病例中,诊断周转时间不足 2 小时,测序后数分钟内即可生成稳健的肿瘤分类。
- 分类器性能与最终整合诊断在 90% 的前瞻性病例中一致。
- ROBIN 可实时检测单核苷酸变异、拷贝数变异和结构变异,并在 24 小时内提供完整整合诊断信息。
临床怎么用
- 作者指出,术中甲基化分类信息可提高涂片诊断的可靠性,并帮助外科医生在手术风险与可能获益之间权衡以调整手术策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Advances in our technological capacity to interrogate CNS tumor biology have led to the ever increasing use of genomic sequencing in diagnostic decision making. Presently, CNS tumors are classified based on their epigenetic signatures, leading to a paradigm shift in diagnostic pathways. Such testing can be performed so rapidly using nanopore sequencing that results can be provided intraoperatively. This information greatly improves the fidelity of smear diagnosis and can help surgeons tailor their approach, balancing the risks of surgery with the likely benefit. Nevertheless, full integrated diagnosis may require subsequent additional assays to detect pathognomonic somatic mutations and structural variants, thereby delaying the time to final diagnosis. METHODS: Here, we present ROBIN, a tool based on PromethION nanopore sequencing technology that can provide both real-time, intraoperative methylome classification and next-day comprehensive molecular profiling within a single assay. ROBIN utilizes 3 methylation classifiers to improve diagnostic performance in the intraoperative setting. RESULTS: We demonstrate classifier performance on 50 prospective intraoperative cases, achieving a diagnostic turnaround time under 2 hours and generating robust tumor classifications within minutes of sequencing. Furthermore, ROBIN can detect single nucleotide variants, copy number variants, and structural variants in real time, and is able to inform a complete integrated diagnosis within 24 hours. Classifier performance demonstrated concordance with final integrated diagnosis in 90% of prospective cases. CONCLUSION: Nanopore sequencing can greatly improve turnaround times for standard-of-care diagnostic testing and is furthermore able to reliably provide clinically actionable intraoperative tumor classification.
引用
- Deacon S, Cahyani I, Holmes N, et al. ROBIN: A unified nanopore-based assay integrating intraoperative methylome classification and next-day comprehensive profiling for ultra-rapid tumor diagnosis. Neuro Oncol. 2025. PMID: 40392954. doi:10.1093/neuonc/noaf103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。